Wedbush Has Optimistic Outlook of argenx Q4 Earnings

argenx SE (NASDAQ:ARGX) – Stock analysts at Wedbush increased their Q4 2024 EPS estimates for argenx in a research report issued to clients and investors on Monday, January 13th. Wedbush analyst D. Nierengarten now expects that the company will earn $2.74 per share for the quarter, up from their previous forecast of $1.09. Wedbush currently has a “Outperform” rating and a $655.00 target price on the stock. The consensus estimate for argenx’s current full-year earnings is $2.17 per share. Wedbush also issued estimates for argenx’s Q1 2025 earnings at $3.11 EPS, Q2 2025 earnings at $4.15 EPS, Q3 2025 earnings at $5.12 EPS, Q4 2025 earnings at $5.95 EPS, FY2025 earnings at $18.37 EPS, FY2026 earnings at $33.33 EPS and FY2027 earnings at $43.65 EPS.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $588.88 million during the quarter, compared to analysts’ expectations of $543.29 million. During the same quarter in the prior year, the company earned ($1.25) EPS.

ARGX has been the subject of a number of other research reports. Scotiabank raised argenx from a “sector perform” rating to a “sector outperform” rating and upped their price target for the stock from $439.00 to $715.00 in a research report on Tuesday, November 5th. Truist Financial restated a “buy” rating and set a $700.00 target price (up previously from $660.00) on shares of argenx in a report on Tuesday. JPMorgan Chase & Co. lifted their price target on shares of argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a research note on Monday, November 4th. JMP Securities increased their price objective on shares of argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research note on Tuesday. Finally, Guggenheim lifted their target price on argenx from $585.00 to $665.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $658.39.

argenx Price Performance

ARGX stock opened at $659.81 on Thursday. The stock has a market capitalization of $39.83 billion, a P/E ratio of -749.78 and a beta of 0.59. argenx has a fifty-two week low of $349.86 and a fifty-two week high of $678.21. The business has a 50-day moving average of $619.30 and a 200-day moving average of $554.23.

Hedge Funds Weigh In On argenx

Several institutional investors and hedge funds have recently modified their holdings of the stock. Point72 Hong Kong Ltd bought a new stake in shares of argenx during the 2nd quarter worth about $76,000. Cromwell Holdings LLC lifted its position in argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after acquiring an additional 66 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of argenx by 47.5% during the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock worth $94,000 after acquiring an additional 56 shares during the period. Blue Trust Inc. grew its position in shares of argenx by 413.9% in the third quarter. Blue Trust Inc. now owns 370 shares of the company’s stock valued at $201,000 after purchasing an additional 298 shares during the last quarter. Finally, Keudell Morrison Wealth Management bought a new position in shares of argenx during the third quarter worth approximately $207,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.